Everything about GLP-1 therapy — medications, dosing, side effects, costs, and how to start. Reviewed by board-certified physicians.
20.9%
Avg. weight loss — tirzepatide 15mg, branded RCT (SURMOUNT-1)
14.9%
Avg. weight loss — semaglutide 2.4mg, branded RCT (STEP-1)
20%
Reduction in cardiovascular events — SELECT trial (branded semaglutide)
5+
FDA-approved GLP-1 brand names for weight management†
About these numbers
These percentages are from the FDA-approved branded medication in a randomized clinical trial (RCT). ThriveAxis dispenses compounded semaglutide and tirzepatide through licensed 503A compounding pharmacies — individual results on compounded formulations may differ and have not been separately established in RCTs. Your provider reviews the current evidence at your consult. See full trial citations →
Medical Disclaimer: This guide is for educational purposes only. It does not constitute medical advice. All treatment decisions require a consultation with a licensed medical provider. Eligibility for GLP-1 therapy is determined by your provider after a proper medical evaluation.
The Basics
Key Takeaway
GLP-1 drugs work when used inside a real protocol. Without a protein target, resistance training, and active provider management, most patients plateau, lose muscle, and regain weight after stopping. ThriveAxis builds the protocol around the medication — not just the prescription.
Clinical Evidence Referenced in This Guide
STEP-1 Trial (NEJM 2021): Branded semaglutide 2.4mg (Wegovy) produced 14.9% mean body weight reduction vs 2.4% placebo over 68 weeks. Compounded formulations have not been separately tested in RCTs.
SELECT Trial (NEJM 2023): Branded semaglutide reduced major cardiovascular events by 20% in patients with obesity and cardiovascular disease.
Testosterone meta-analysis (JAMA 2020): TRT in men with hypogonadism produced significant improvements in lean body mass, sexual function, and mood.
All protocols at ThriveAxis are reviewed by Michael Harrington MD against current published literature.
What is a GLP-1?
GLP-1 stands for Glucagon-Like Peptide-1 — a hormone your gut produces naturally every time you eat. Its job is to signal your brain that food has arrived, slow the rate at which your stomach empties, and trigger your pancreas to release insulin in proportion to blood sugar levels.
In people with obesity and type 2 diabetes, this signaling system is impaired. The GLP-1 response is blunted — meaning the "I'm full" signal arrives too late, too weakly, or not at all. This is not a character flaw. It is a documented physiological difference that research has confirmed across thousands of patients.
GLP-1 receptor agonists are medications designed to activate the GLP-1 receptor with far greater potency and duration than the naturally occurring hormone. They essentially turn the volume up on a signaling system that obesity has turned down.
Why GLP-1s are different from every other weight loss approach
They work at the neurological level — in the brain itself, not just the stomach. Many patients report reduced preoccupation with food (commonly referred to as "food noise"); this qualitative change in relationship with food has been widely reported in both published observational studies and patient-reported outcomes in GLP-1 trials. This is a fundamentally different mechanism from calorie restriction or metabolism-boosting supplements. Individual experience varies.
A brief history
The GLP-1 receptor was identified in the 1980s. The first GLP-1 receptor agonist, Exenatide (Byetta), was approved by the FDA in 2005 for type 2 diabetes. Liraglutide (Victoza/Saxenda) followed in 2010. Semaglutide (Ozempic) was approved for diabetes in 2017, and its higher-dose formulation Wegovy received FDA approval for chronic weight management in 2021. Tirzepatide — the first dual GLP-1/GIP agonist — received approval as Mounjaro in 2022 and as Zepbound for weight loss in 2023.
We are in the third generation of GLP-1 therapy. The science has been building for four decades. This is not a fad.
Mechanism of Action
How GLP-1s actually work.
GLP-1 receptor agonists work through multiple simultaneous mechanisms. Understanding this helps set realistic expectations and explains why they work where other approaches have failed.
1. Central appetite suppression
GLP-1 receptors are expressed in the hypothalamus and brainstem — the brain regions that regulate hunger, satiety, and reward-based eating. Activating these receptors reduces the brain's appetite signals and diminishes the reward response to food. Patients consistently describe a reduction in food preoccupation — "I just don't think about food the way I used to."
2. Gastric emptying delay
GLP-1 slows the rate at which food moves from the stomach into the small intestine. Slower gastric emptying means you feel full longer after smaller portions. This is a direct mechanical mechanism — separate from any central appetite effect — that reduces total caloric intake throughout the day.
3. Insulin response optimization
GLP-1 stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner — meaning it only triggers insulin release when blood sugar is actually elevated. This is critically important: it dramatically reduces the risk of hypoglycemia compared to older diabetes medications that trigger insulin release regardless of blood sugar levels.
4. Glucagon suppression
Glucagon is the opposing hormone to insulin — it raises blood sugar by triggering the liver to release stored glucose. GLP-1 agonists suppress glucagon secretion, reducing inappropriate blood sugar elevation between meals.
5. GIP receptor activation (tirzepatide only)
Tirzepatide adds a second mechanism by also activating the GIP (Glucose-Dependent Insulinotropic Polypeptide) receptor. GIP enhances the metabolic effects of GLP-1, improves insulin sensitivity in peripheral tissues, and appears to reduce GI side effects. This dual-agonism is why tirzepatide consistently outperforms semaglutide in head-to-head comparisons.
The critical point: These medications work because obesity is a neurohormonal disease — not a willpower problem. GLP-1 agonists correct a documented biological impairment. The clinical results reflect this. In pivotal FDA trials, semaglutide 2.4 mg produced approximately 14.9% average body weight reduction over 68 weeks (STEP-1, NEJM 2021) and tirzepatide 15 mg produced approximately 20.9% over 72 weeks (SURMOUNT-1, NEJM 2022) — exceeding prior pharmacological weight-loss therapies. Individual results vary. See /disclosures for the branded-vs-compounded disclaimer.
"I stopped counting calories. I started living my life."
Individual member on GLP-1 + Nutrition Protocol — 38 lbs in 6 months. Results not typical; individual outcomes vary by dose, adherence, training, baseline labs, and other factors.
Four major GLP-1 medications dominate the market in 2026, across two active pharmaceutical ingredients. Here is the complete breakdown of each.
Wegovy®
Semaglutide 2.4mg — Novo Nordisk
FDA ApprovedWeight Loss
14.9%average body weight loss — branded semaglutide (Wegovy), STEP-1 trial, 68 weeks
IndicationChronic weight management
DosingWeekly subcut. injection
Max dose2.4mg weekly
List price~$1,350/month
AvailabilityIn stock 2026
Ozempic®
Semaglutide 0.5–2mg — Novo Nordisk
FDA ApprovedType 2 Diabetes
~12%average weight loss at 1mg dose — SUSTAIN trials
IndicationType 2 diabetes (off-label weight)
DosingWeekly subcut. injection
Max dose2mg weekly
List price~$900/month
CV benefitSELECT trial — 20% risk reduction
Zepbound®
Tirzepatide 2.5–15mg — Eli Lilly
FDA ApprovedWeight Loss
20.9%average body weight loss — branded tirzepatide (Zepbound), SURMOUNT-1, 72 weeks, 15mg
IndicationChronic weight management
DosingWeekly subcut. injection
Max dose15mg weekly
List price~$1,060/month
MechanismDual GLP-1 + GIP agonist
Mounjaro®
Tirzepatide 2.5–15mg — Eli Lilly
FDA ApprovedType 2 Diabetes
~2.5%A1C reduction at 15mg — SURPASS-2 vs semaglutide 1mg
IndicationType 2 diabetes (off-label weight)
DosingWeekly subcut. injection
Max dose15mg weekly
List price~$1,020/month
A1C advantageSuperior to semaglutide
2026 Regulatory Update: The FDA resolved the tirzepatide drug shortage and ended enforcement discretion for compounding pharmacies producing tirzepatide. Multiple telehealth companies received FDA warning letters. Compounded tirzepatide availability has changed significantly. ThriveAxis providers advise patients on currently available and legally compliant options at every consultation.
Compounded semaglutide in 2026
Compounded semaglutide remains more widely available than compounded tirzepatide following the 2026 FDA enforcement actions on tirzepatide compounding. Compounded semaglutide is prepared by state-licensed 503A compounding pharmacies and is significantly less expensive than brand-name Wegovy. It contains the same active pharmaceutical ingredient but has not been evaluated by the FDA for safety, efficacy, or quality. Your ThriveAxis provider will discuss current compounding options at your consultation.
Head to Head
Semaglutide vs Tirzepatide — the complete comparison.
These are the two dominant GLP-1 medications. Here is an honest, data-driven comparison of everything that matters.
Maximum weight loss, T2D management, fewer GI side effects
Bottom line: Tirzepatide produces greater average weight loss in clinical trials. But it is not the right choice for every patient. Semaglutide has stronger cardiovascular outcome data, a longer safety record, and better compounded medication availability in 2026. Your ThriveAxis provider recommends based on your specific goals, health history, and what is currently available.
Eligibility
Who qualifies for GLP-1 therapy?
FDA approval criteria are clear, but clinical practice often extends beyond the strict indications when a provider determines it is medically appropriate. Here is how eligibility breaks down.
Typically Qualifies
BMI 30 or higher
FDA-indicated for chronic weight management at all FDA-approved GLP-1 doses. No additional conditions required.
Typically Qualifies
BMI 27+ with weight-related condition
Hypertension, type 2 diabetes, dyslipidemia, sleep apnea, or cardiovascular disease qualify as comorbidities under FDA labeling.
Strong Candidate
Type 2 Diabetes
All GLP-1 medications are approved for T2D management. Dual benefit — blood sugar control plus weight reduction. Often covered by insurance for this indication.
Provider Determination Required
BMI 25-27, no conditions
Below standard FDA indication. Some providers prescribe off-label based on clinical judgment and patient-specific factors. Requires thorough evaluation.
Contraindicated — Discuss First
History of MTC or MEN2
Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 is a contraindication for all GLP-1 receptor agonists.
Requires Careful Evaluation
Pregnancy, severe GI disease, pancreatitis history
Not recommended during pregnancy. History of pancreatitis, severe gastroparesis, or inflammatory bowel disease requires careful provider evaluation before prescribing.
The fastest way to determine your specific eligibility is to complete the ThriveAxis free assessment and meet with your matched provider. There is no commitment required and the assessment takes 90 seconds.
Getting Started
How to start GLP-1 therapy.
The process from first interest to first injection takes about 7-10 days through ThriveAxis. Here is every step.
1
Day 1 — 5 minutes
Complete your free health assessment
9-step online assessment covering your goals, health history, current medications, and eligibility indicators. No commitment required. Takes 90 seconds to 5 minutes.
2
Day 1 — after assessment
Choose your membership plan and enroll
Select Foundation ($149/mo), Optimizer ($249/mo), or Total Optimization ($399/mo). GLP-1 access is included in all plans. Medications billed separately.
3
Day 1-2 — in your portal
Upload existing bloodwork (optional but recommended)
Recent labs help your provider personalize your starting dose. If you don't have labs, your provider will advise on what to order. Not required to start the process.
4
Day 1-2 — required
Video consultation with your licensed provider
A 20-30 minute video visit with your matched MD, NP, or PA. They review your intake, ask follow-up questions, confirm eligibility, explain your options, and prescribe if appropriate. This consultation is required — no exceptions.
5
Day 2-4
Prescription sent to pharmacy
Your provider sends your prescription to a licensed compounding or retail pharmacy. The pharmacy verifies the prescription and prepares your first month's supply.
6
Day 5-7
Medications shipped to your door
Shipped in temperature-controlled packaging via FedEx or UPS with tracking. Discreet exterior packaging with no ThriveAxis branding. Arrives with administration supplies and instructions.
7
Day 7-10 — your first dose
Portal activates your full protocol
Your accountability calendar loads with dose day reminders, weigh-in schedules, and lab due dates. Your dosing calculator is pre-configured for your specific medication and dose. Your plan is live.
Dosing Schedules
"On the right protocol, most patients see meaningful weight change within the first four weeks."
Titration schedules — both medications.
GLP-1 medications are always started at the lowest dose and increased gradually over months. This slow titration is the key to minimizing side effects. Do not rush it. Every step up should be comfortable before advancing.
Semaglutide (Wegovy®) — FDA titration schedule
Weeks
Phase
Dose
Notes
1–4
Initiation
0.25mg weekly
Starting dose — not a therapeutic dose. Building tolerance.
5–8
Escalation 1
0.5mg weekly
First therapeutic dose. Appetite reduction begins here for most patients.
9–12
Escalation 2
1.0mg weekly
Significant appetite suppression. Weight loss accelerates.
13–16
Escalation 3
1.7mg weekly
Near-maximum dose. Provider may hold here if tolerating well and losing weight.
17+
Maintenance
2.4mg weekly
Maximum approved dose. Provider determines if escalation is appropriate.
Tirzepatide (Zepbound®) — FDA titration schedule
Weeks
Phase
Dose
Notes
1–4
Initiation
2.5mg weekly
Starting dose. Not a therapeutic dose. Tolerance building.
5–8
Escalation 1
5mg weekly
First therapeutic dose. Most patients notice meaningful appetite reduction.
9–12
Escalation 2
7.5mg weekly
Weight loss typically well established by this point.
13–16
Escalation 3
10mg weekly
Many patients achieve their goals at this dose without needing to escalate further.
17–20
Escalation 4
12.5mg weekly
For patients needing additional efficacy.
21+
Maintenance
15mg weekly
Maximum approved dose. Not all patients need or tolerate 15mg.
Important: Your ThriveAxis provider may adjust this schedule based on your individual response, tolerance, and goals. The FDA schedules above are the approved standard. Some patients stay at lower doses where they are comfortable and getting results — maximum dose is not always necessary or appropriate.
Timeline of Results
What to expect — week by week.
1-2
Weeks 1–2
Appetite begins to shift
Most patients notice a reduction in between-meal hunger and food preoccupation. Some report nausea — usually mild and related to the first dose. Weight change is minimal. Focus on hydration and small portions.
3-8
Weeks 3–8
Measurable weight loss begins
Average weight loss in the first 4-8 weeks is 2-5% of body weight. The "food noise" reduction becomes more pronounced. Many patients report this as the most significant psychological shift — eating becomes intentional rather than compulsive.
3mo
Month 3 — first major milestone
5–10% body weight reduction
At the 5-10% threshold, clinically significant health improvements begin — blood pressure reduction, improved insulin sensitivity, reduced joint stress. Many patients begin getting positive feedback from their bloodwork. Motivation is typically high at this point.
6mo
Month 6
Approaching 10–15% body weight loss
The rate of loss typically slows as the body adapts. This is normal and expected — not a plateau in the traditional sense. Dose is often at or near maximum. Body composition is visibly changing. Lab markers like HbA1c, triglycerides, and blood pressure often dramatically improved.
12mo
Month 12 — major results
15–21% body weight reduction (average)
Clinical trials run 68-72 weeks. The full weight-loss trajectory plays out over this full period; STEP-1 reported ≈14.9% body weight reduction for semaglutide and SURMOUNT-1 reported ≈20.9% for tirzepatide at maximum tolerated doses. In our experience, members who stay consistent and pair medication with the ThriveAxis nutrition and fitness protocol tend to match or exceed these trial benchmarks, likely because of integrated lifestyle support. Individual results vary.
What to Manage
Side effects — and how to actually manage them.
Most GLP-1 side effects are gastrointestinal and occur during dose escalation. The majority are mild and resolve within the first 4-8 weeks. Slow titration is the single most effective prevention strategy.
Nausea — Most Common
Occurs in approximately 20-44% of patients per pivotal trials (STEP-1: 44% for semaglutide 2.4 mg; SURMOUNT-1: 25-33% across tirzepatide doses), typically in the first 4-8 weeks. Usually mild to moderate. Management: Eat small, bland meals. Avoid fatty, spicy, or heavy foods. Do not eat to the point of fullness. Ginger tea and anti-nausea gum can help. Most patients adapt within 4-6 weeks. Dose escalation should be paused if nausea is severe.
Constipation — Common
Occurs in 10-24% of patients. Gastric emptying slows, which slows the entire GI tract. Management: Hydration is critical — aim for 2-3 liters of water daily. Increase dietary fiber. Magnesium glycinate at night. Gentle movement after meals. Stool softeners if needed. Discuss with your provider if severe or persistent.
Vomiting — Less Common
Occurs in 5-15% of patients, more often with rapid dose escalation. Management: Slow titration prevents most vomiting. Eat very slowly. Stop eating the moment you feel full — before you normally would. If vomiting persists, your provider should hold the dose escalation and may prescribe ondansetron or promethazine temporarily.
Fatigue — Early
Common in the first 2-4 weeks as caloric intake drops significantly. Management: Adequate protein intake is essential — aim for 1g per pound of body weight or more. Electrolytes (especially sodium and potassium) help. Iron levels should be monitored. Fatigue typically resolves as the body adapts.
Injection Site Reactions — Occasional
Redness, swelling, or itching at the injection site in some patients. Management: Rotate injection sites — abdomen, thigh, upper arm. Allow medication to reach room temperature before injecting. Inject slowly. Most reactions are mild and self-limiting.
Muscle Loss — Monitor Carefully
Rapid weight loss on GLP-1s can include muscle loss alongside fat loss. Management: This is why ThriveAxis integrates strength training into your protocol. Resistance exercise 3x per week and high protein intake preserve muscle mass during GLP-1 therapy. This is a known issue the fitness program specifically addresses.
Serious but rare risks: Pancreatitis, gallbladder disease, acute kidney injury (from dehydration), and worsening diabetic retinopathy in patients with diabetes. Discontinue and contact your provider immediately if you experience severe abdominal pain, persistent vomiting, or vision changes. GLP-1 medications are contraindicated with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Nutrition Strategy
What to eat on GLP-1 therapy.
GLP-1 medications dramatically reduce appetite — but they do not choose what you eat. The quality of your reduced caloric intake matters enormously for body composition, muscle preservation, and long-term results.
Prioritize protein above everything else
When appetite is suppressed, patients often under-eat protein — the most critical macronutrient for muscle preservation during weight loss. Target 1 gram of protein per pound of body weight daily (or 1g per pound of goal weight if you are significantly over). Lean meats, eggs, Greek yogurt, cottage cheese, and protein shakes all work. Your ThriveAxis nutrition plan is calibrated specifically to your protocol.
Foods that work well on GLP-1s
Lean proteins: Chicken, turkey, fish, eggs, Greek yogurt — gentle on a sensitive stomach and high in protein
Low-fat options: High-fat foods slow gastric emptying further, amplifying GI side effects on GLP-1s
Soft textures: Especially during the first 4-8 weeks when GI sensitivity is highest
Small, frequent meals: 4-5 small meals rather than 2-3 large ones — reduces GI distress
Foods that tend to cause problems
High-fat foods: Fried foods, fast food, heavy sauces — dramatically worsen nausea
Alcohol: Increases hypoglycemia risk in patients with diabetes. Generally poorly tolerated. Many patients lose interest in alcohol on GLP-1s.
Carbonated beverages: Increase bloating and GI discomfort
Large meals: The biggest mistake patients make — eating the same sized portion they ate before starting. Start with half portions.
The muscle preservation equation: Protein + resistance training = preserved muscle during GLP-1 weight loss. Patients who do not prioritize both lose significant muscle alongside fat. ThriveAxis is one of the few telehealth platforms that provides a custom fitness program specifically designed around your GLP-1 protocol — this is not an add-on, it is a clinical requirement for optimal results.
Long-Term Considerations
If you stop GLP-1 therapy — what actually happens.
This is the question most telehealth providers avoid answering honestly. We will not.
The honest data on weight regain
Clinical studies show that most patients regain a significant portion of lost weight after stopping GLP-1 therapy. The STEP-4 trial (semaglutide withdrawal) showed an average regain of approximately 7% body weight within 1 year of stopping — compared to continued 7.9% weight loss in patients who stayed on the medication. By 2 years, most of the regained weight returns.
This is not a failure of the medication or the patient. Obesity is a chronic condition driven by biology. GLP-1 medications are treating the underlying physiology — when they are removed, the physiology reasserts itself.
What changes this outcome
The patients who maintain the most weight after stopping are those who used their time on GLP-1 therapy to build genuinely sustainable habits — not just ate less, but restructured their relationship with food and built a consistent exercise practice. This is precisely why ThriveAxis builds nutrition and fitness programming into your GLP-1 protocol from day one. The medication creates the window. The habits fill it permanently.
Long-term GLP-1 therapy
Many physicians now treat GLP-1 therapy the same way they treat blood pressure medication — as an ongoing management tool for a chronic condition, not a finite course. The cardiovascular benefits demonstrated in the SELECT trial (semaglutide) suggest long-term use has benefits beyond weight loss. Your ThriveAxis provider discusses your individual long-term plan at each quarterly review.
The ThriveAxis philosophy on this
We believe the goal of GLP-1 therapy is not just weight loss — it is the restoration of health and the building of a life where maintaining that health is sustainable. We build every protocol around that outcome, not around the number on a scale at week 12.
Access & Pricing
"GLP-1 works best inside a complete clinical protocol — not as a standalone prescription."
What GLP-1 therapy actually costs in 2026.
The price landscape for GLP-1 medications is complex. Here is a transparent breakdown of what you will actually pay through different channels.
Brand-Name — Retail Pharmacy
$1,350
per month
Wegovy without insurance. Ozempic ~$900. Zepbound ~$1,060. GoodRx savings available but modest. Most patients not eligible for manufacturer programs.
Insurance — With Prior Auth
$0–$150
per month (copay)
Employer insurance rarely covers Wegovy. Medicare does not cover weight loss drugs (coverage for T2D indication exists). Medicaid varies by state. Prior authorization process is extensive.
Plus ThriveAxis membership from $149/mo. Compounded semaglutide through licensed 503A pharmacies. Provider determines dose. More accessible pricing than brand-name.
GLP-1-only platforms
Varies
per month
Pricing and membership terms vary by provider. Typically GLP-1 only — no TRT, hormones, or peptides included. Review each provider's current pricing directly.
Hims & Hers
$39 → $199+
intro first month → ongoing
Introductory first month $39; injectable semaglutide subscriptions listed around $199/mo ongoing, higher doses up to $1,899/mo. Weight loss focus — no TRT, no peptide therapy. Retrieved from forhims.com 2026-04-24.
Ro / Ro Body
$39 → $74–149 + med
first month → ongoing membership + medication
Ro Body membership: $39 first month, then $74/mo (annual) to $149/mo (monthly). Medication billed separately — Wegovy pill $149 first month / $199–$299 thereafter; Zepbound KwikPen cash $299–$449/mo. GLP-1 focus — injectable TRT not offered. Retrieved from ro.co/weight-loss/pricing 2026-04-24.
Competitor pricing reflects public rates retrieved from each provider's official site on 2026-04-24. Prices change frequently; verify at source before comparing. Sources: ro.co, forhims.com.
HSA and FSA use
Both ThriveAxis membership fees and prescription medications are generally eligible for HSA/FSA reimbursement as medical expenses prescribed by a licensed provider. Confirm with your plan administrator. We provide itemized receipts for all charges to support reimbursement submissions.
Can I use a GLP-1 coupon or manufacturer discount?
Novo Nordisk and Eli Lilly offer savings programs for brand-name GLP-1 medications. Wegovy's savings program can reduce out-of-pocket costs to as low as $0/month for eligible commercially insured patients. These programs typically do not apply to Medicare or Medicaid patients. Eligibility requirements vary. Your ThriveAxis provider can advise on which programs you may qualify for.
Quick Answers
GLP-1 FAQ.
GLP-1 receptor agonists are not FDA-approved for type 1 diabetes. Some research suggests potential benefit in T1D, but the evidence base is limited and the risk profile is more complex — particularly regarding diabetic ketoacidosis management. Your ThriveAxis provider will evaluate your specific situation and discuss whether off-label use could be appropriate based on your individual clinical profile, including a frank discussion of the specific risks associated with GLP-1 use in type 1 diabetes.
The most important interactions to discuss with your provider include: insulin and sulfonylureas (hypoglycemia risk), oral medications in general (delayed gastric emptying affects absorption timing — take critical medications 1 hour before injection), and warfarin (INR monitoring may be needed). Always disclose every medication, supplement, and herbal product at your consultation. This is one of the most important reasons the required provider visit exists.
Not only is it safe — it is essential. Exercise, specifically resistance training, is the primary tool for preserving muscle mass during GLP-1-assisted weight loss. Patients who combine GLP-1 therapy with consistent strength training retain significantly more muscle and achieve better body composition outcomes than those who rely on the medication alone. ThriveAxis provides a custom fitness program specifically designed around your GLP-1 protocol.
Alcohol is not strictly contraindicated, but most patients find they tolerate it poorly on GLP-1s — nausea is amplified, and alcohol on an already-sensitive stomach is difficult. Alcohol also adds empty calories that work against your goals and can increase hypoglycemia risk in diabetic patients. Many patients report that GLP-1 therapy significantly reduces their desire for alcohol — this appears to be a real neurological effect related to the reward system changes these medications produce.
Unopened GLP-1 vials and pens should be stored in the refrigerator at 35-46°F (2-8°C). Once opened, Wegovy pens can be stored at room temperature (up to 77°F / 25°C) for up to 28 days — do not refrigerate after first use for auto-injector pens. Compounded semaglutide vials are typically stored refrigerated before and after opening. Never freeze GLP-1 medications. Never use a medication that has been frozen, appears cloudy, or has particles. Check your specific medication's packaging for its storage instructions — they can vary.
True non-response to GLP-1s is rare. What appears to be a plateau is usually one of three things: you have reached your metabolic set point at your current dose, caloric intake has unconsciously increased, or the dose needs adjustment. Your ThriveAxis provider reviews your progress monthly and can adjust your protocol. If you are genuinely not responding to one GLP-1 medication, switching to the other (semaglutide to tirzepatide or vice versa) is a clinically supported option.
A GLP-1 receptor agonist is a prescription medication that mimics glucagon-like peptide-1, a hormone produced in the gut after eating. These drugs slow gastric emptying, suppress appetite in the brain, and improve insulin signaling. In clinical trials, they produce average weight loss of 15–22% of body weight over 68–72 weeks.
Most patients notice reduced appetite within the first one to two weeks. Measurable weight loss (1–5 lbs) typically occurs by weeks four to eight. The full titration schedule spans 16–20 weeks, and maximum weight loss is usually achieved between months six and twelve of continuous treatment. Individual results vary based on diet, activity, and dose.
The FDA-approved starting dose for Wegovy (semaglutide) is 0.25 mg injected subcutaneously once weekly for four weeks. The dose is then increased in four-week increments — 0.5 mg, 1.0 mg, 1.7 mg — before reaching the maintenance dose of 2.4 mg weekly. Titration is designed to minimize nausea.
FDA-approved GLP-1 therapy (Wegovy, Zepbound) is indicated for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol. A licensed provider must evaluate your health history before prescribing.
The most common side effects are nausea (~44%), diarrhea (~30%), vomiting (~24%), and constipation (~24%), occurring most frequently during dose escalation. These typically improve as the body adjusts. Rare but serious risks include pancreatitis, gallbladder disease, and — in patients with a personal or family history — thyroid C-cell tumors.
Yes. Semaglutide can be prescribed online through licensed telehealth providers. The process requires a medical consultation with a provider licensed in your state, a health history review, and a valid prescription. The prescription is then filled by a licensed pharmacy and shipped to your door. You cannot legally obtain semaglutide without a prescription from a licensed provider.
Compounded semaglutide remains legal under limited circumstances in 2026. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed compounding pharmacy may compound semaglutide for a patient with a documented medical need that cannot be met by the FDA-approved product. Cost savings or convenience alone does not qualify. The FDA resolved the semaglutide shortage in February 2025; availability of compounded versions has changed significantly as a result.
Brand-name Wegovy costs approximately $1,350/month without insurance in 2026. Zepbound (tirzepatide) is approximately $1,060/month. Through telehealth platforms using compounded semaglutide or tirzepatide (where legally available), monthly costs typically range from $150–$400 for medication plus provider access. ThriveAxis membership starts at $149/month; medication is billed separately based on your provider's protocol.
Prioritize protein (0.7–1g per pound of body weight) to preserve muscle during weight loss. Include easy-to-digest foods like eggs, Greek yogurt, lean fish, and cooked vegetables. Avoid high-fat, high-sugar foods that worsen nausea. Small, frequent meals (4–6 per day) are better tolerated than large meals. Staying hydrated is critical — dehydration worsens GLP-1 side effects.
Most patients regain a significant portion of lost weight after stopping GLP-1 therapy. The STEP-4 trial found that patients who discontinued semaglutide regained approximately two-thirds of lost weight within one year. GLP-1 receptors return to baseline function after discontinuation. Long-term GLP-1 use or transition to a lower maintenance dose is often recommended for weight maintenance.
GLP-1 medications reduce overall body weight, but 25–39% of weight lost can be lean muscle mass in the absence of resistance training and adequate protein intake. Preserving muscle requires deliberate effort: consuming 0.7–1g protein per pound of body weight daily and performing resistance training 2–3 times per week. ThriveAxis combines GLP-1 protocols with fitness coaching specifically to address this risk.
Yes. Prescription GLP-1 medications (Wegovy, Zepbound) are FSA- and HSA-eligible when prescribed by a licensed provider for a qualifying medical condition. Compounded versions may also qualify depending on your plan administrator's interpretation. Telehealth consultation fees are generally FSA/HSA-eligible. Confirm eligibility with your specific plan before purchasing.
Tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) is a dual-agonist that activates both GLP-1 and GIP receptors. Ozempic (semaglutide) activates only the GLP-1 receptor. Tirzepatide produces greater average weight loss — up to 22.5% vs approximately 14.9% for semaglutide. Ozempic is FDA-approved for type 2 diabetes; Wegovy (same molecule, higher dose) is the weight-loss-approved version of semaglutide.
Yes, and this combination is a core ThriveAxis protocol. GLP-1 medications support fat loss; testosterone replacement (in men) and BHRT (in women) help preserve muscle mass and metabolic rate during caloric restriction. A licensed provider must evaluate whether combination therapy is appropriate for your individual case.
GLP-1 receptors in the hypothalamus — specifically the arcuate nucleus — respond to GLP-1 agonists by reducing appetite signaling and increasing satiety signals. The result is significantly reduced caloric intake without willpower. GLP-1 receptors are also present in the brainstem (affecting nausea) and reward circuits (affecting food cravings). This multi-site brain action is why GLP-1 medications outperform behavioral interventions alone.
Long-term cardiovascular data is increasingly positive. The SELECT trial (2023) showed semaglutide reduced major cardiovascular events by 20% in overweight or obese patients with existing cardiovascular disease. Long-term thyroid C-cell safety monitoring is recommended for all GLP-1 users. Most providers recommend periodic blood work, including a thyroid panel, every 6–12 months for patients on long-term GLP-1 therapy.
Ready to start your GLP-1 protocol?
Complete your free assessment and get matched with a licensed provider in your state within 48 hours.
Gained 15 lbs of lean muscle. Dropped body fat. TRT + peptide protocol. Documented with photos throughout. Results not typical. Individual results vary. Protocol details.
